News coverage about Kite Pharma (NASDAQ:KITE) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kite Pharma earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.8451457892985 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

Kite Pharma (KITE) remained flat at $$179.79 on Tuesday. The stock has a market capitalization of $10,280.00 and a price-to-earnings ratio of -26.06. Kite Pharma has a 12 month low of $39.82 and a 12 month high of $179.95.

WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/01/09/kite-pharma-kite-earns-news-sentiment-rating-of-0-15.html.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Stock Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related stocks with our FREE daily email newsletter.